Table 2.
Subgroup analyses for screening the major and minor criteria of the algorithm
| Factors | No. of studies | No. of cases | Infection control, % (95% CI) | RR (95% CI) | p value |
|---|---|---|---|---|---|
| Symptom duration | |||||
| < 3 weeks | 16 | 357 | 71.15 (66–76) | 0.35 (0.27–0.45) | 0.000 |
| > 3 weeks | 8 | 57 | 35.09 (23–47) | ||
| Bacterial species | |||||
| MRSA | 6 | 40 | 35 (19.6–50.4) | 2.06 (1.5–2.8) | 0.000 |
| Non-MRSA | 168 | 68.5 (61.4–75.6) | |||
| Immune situation | |||||
| RA | 5 | 38 | 44.7 (29–61) | 1.3 (0.93–1.83) | 0.201 |
| Non-RA | 151 | 57.6 (50–65) | |||
| Surgical procedure | |||||
| Open debridement and liner exchange | 11 | 173 | 74 (67–81) | 0.82 (0.52–1.28) | 0.394 |
| Arthroscopic debridement and liner retention | 4 | 54 | 66.7 (54–79) | ||
RR relative risk, MRSA methicillin-resistant Staphylococcus aureus, RA rheumatoid arthritis